History of Esophagogastric Junction Cancer Treatment and Current Surgical Management in Western Countries

다국어 초록 (Multilingual Abstract)

The incidence of esophagogastric junction (EGJ) cancer has been significantly increasing in Western countries. Appropriate planning for surgical therapy requires a reliable classification of EGJ cancers with respect to their exact location. Clinically, the most accepted classification of EGJ cancers is “adenocarcinoma of the EGJ” (AEG or “Siewert”), which divides tumor center localization into AEG type I (distal esophagus), AEG type II (“true junction”), and AEG type III (subcardial stomach). Treatment strategies in western countries routinely employ perioperative chemotherapy or neoadjuvant chemoradiation for cases of locally advanced cancers. The standard surgical treatment strategies are esophagectomy for AEG type I and gastrectomy for AEG type III cancers. For “true junctional cancers,” i.e., AEG type II, whether the extension of resection in the oral or aboral direction represents the most effective surgical therapy remains debatable. This article reviews the history of surgical EGJ cancer treatment and current surgical strategies from a Western perspective.

참고문헌 (Reference)

1 Berlth F, "Total minimally invasive esophagectomy for esophageal adenocarcinoma reduces postoperative pain and pneumonia compared to hybrid esophagectomy" 32 : 4957-4965, 2018

2 Sonnenberg A, "Time trends of mortality from gastric cancer in Europe" 56 : 1112-1118, 2011

3 Lerut T, "Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma" 240 : 962-972, 2004

4 Fitzmaurice C, "The global burden of cancer 2013" 1 : 505-527, 2015

5 Al-Batran SE, "The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI" 17 : 893-, 2017

6 Katai H, "Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912" 20 : 699-708, 2017

7 Yamashita H, "Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma" 20 : 69-83, 2017

8 van Hagen P, "Preoperative chemoradiotherapy for esophageal or junctional cancer" 366 : 2074-2084, 2012

9 Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer" 355 : 11-20, 2006

10 Ychou M, "Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial" 29 : 1715-1721, 2011

11 Sasako M, "Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial" 7 : 644-651, 2006

12 Takiguchi S, "Laparoscopic mediastinal dissection via an open left diaphragm approach for advanced Siewert type II adenocarcinoma" 46 : 129-134, 2016

13 Japanese Gastric Cancer Association, "Japanese gastric cancer treatment guidelines 2014 (ver. 4)" 20 : 1-19, 2017

14 Japanese Gastric Cancer Association, "Japanese classification of gastric carcinoma: 3rd English edition" 14 : 101-112, 2011

15 "Japan Esophageal SocietyJapanese classification of esophageal cancer, 11th edition: part II and III" 14 : 37-65, 2017

16 Moehler M, "German S3-guideline "diagnosis and treatment of esophagogastric cancer"" 49 : 461-531, 2011

17 Hulscher JB, "Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus" 347 : 1662-1669, 2002

18 Buas MF, "Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease" 23 : 3-9, 2013

19 Briez N, "Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications" 99 : 1547-1553, 2012

20 Kim HH, "Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial" 5 : 506-513, 2019

21 Bonavina L, "Early outcome of thoracoscopic and hybrid esophagectomy: propensity-matched comparative analysis" 159 : 1073-1081, 2016

22 Schmidt HM, "Defining benchmarks for transthoracic esophagectomy: a multicenter analysis of total minimally invasive esophagectomy in low risk patients" 266 : 814-821, 2017

23 Siewert JR, "Classification of adenocarcinoma of the oesophagogastric junction" 85 : 1457-1459, 1998

24 Siewert JR, "Cardia cancer: attempt at a therapeutically relevant classification" 58 : 25-32, 1987

25 Siewert JR, "Carcinoma of the cardia: carcinoma of the gastroesophageal junction - classification, pathology and extent of resection" 9 : 173-182, 1996

26 Low DE, "Benchmarking complications associated with esophagectomy" 269 : 291-298, 2019

27 Rüdiger Siewert J, "Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients" 232 : 353-361, 2000

28 Seesing MF, "A propensity score matched analysis of open versus minimally invasive transthoracic esophagectomy in the Netherlands" 266 : 839-846, 2017